The University of Texas System

Sangamo Therapeutics, Inc.

Sangamo Biosciences, Inc.

Laurence J N Cooper

Bipulendu Jena

Natalya Belousova

Edward J Rebar

Jeffrey C Miller

Fyodor Urnov

Michael C Holmes

Philip D Gregory

Andreas Reik

Trevor Collingwood

Simon Olivares

Ana Beatriz Korngold

Brian A Rabinovich

Harjeet Singh

Hiroki Torikai

Feng Wang-Johanning

Ling Zhang

Helen Huls

Lenka Hurton

Janani Krishnamurthy

Sourindra Maiti

David Rushworth

Drew C Deniger

Horoki Torikai

Transposase polypeptides and polynucleotides are provided, which have a high activity in mammalian cells. Methods for engineering cells, such as chimeric antigen T-cells, with the transposes are also provided.

Transposase polypeptides and uses thereof

Provided are methods of generating chimeric antigen receptors (CAR). In some embodiments, library screening of CAR is performed by generating a vector encoding the CAR from random attachment of vectors from libraries of vectors encoding antigen-binding domains (e.g., scFv regions), hinge regions, and endodomains. In some embodiments, the vectors contain a transposon.

Chimeric antigen receptors and methods of making

The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.

Human application of engineered chimeric antigen receptor (CAR) T-cells

Antibodies and antigen binding fragments thereof are provided that bind to T-cell receptors (e.g., TCR&#x3b1;), essentially independent of T-cell epitope specificity. Methods for manipulation of T-cells and methods of treatment using such antibodies are likewise provided.

T-cell receptor (TCR)-binding antibodies and uses thereof

Disclosed herein are methods and compositions for modulating the expression of a HLA locus or for selectively deleting or manipulating a HLA locus or HLA regulator.

Methods and compositions for modification of a HLA locus

In some aspects, isolated transgenic cells (e.g., transgenic T cells) are provided that comprise or express a transgene and DHFRand/or TYMS. Methods for selecting transgenic cells are also provided.

Selection methods for genetically-modified T cells

Chimeric antigen receptor (CAR) constructs are provided that are able to selectively bind to specific protein complexes, such as HER 1/HER3 heterodimer receptors. CAR T-cells comprising these constructs can be used to safely and efficiently target cancer cells expressing specific protein complexes.

Chimeric antigen receptors (CAR) to selectively target protein complexes

Provided herein is a method of expanding clinically-relevant quantities of polyclonal &#x3b3;&#x3b4; T cells that have anti-tumor, anti-viral, and anti-bacterial reactivity. Polyclonal &#x3b3;&#x3b4; T cells can target a variety of tumors, including solid tumors as well as other conditions, such as viral and bacterial infections.

Polyclonal gamma delta T cells for immunotherapy

Provided are monoclonal antibodies that detect CD 19 CAR-modified immune cells and CAR-modified immune cells irrespective of the tumor associated antigen they target. Methods of using these functional monoclonal antibodies include, but are not limited to, detection, quantification, activation, and selective propagation of CAR-modified immune cells.

Anti-CD19 scFv (FMC63) polypeptide

Growing community of inventors

Houston, TX, United States of America

Laurence J N Cooper